YARROW BIOSCIENCE, INC. Financials
This page shows YARROW BIOSCIENCE, INC. (YARW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
We are recalculating YARROW BIOSCIENCE, INC.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
YARROW BIOSCIENCE, INC. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, YARROW BIOSCIENCE, INC. generates $1.25 in operating cash flow (-$33.1M OCF vs -$26.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
YARROW BIOSCIENCE, INC. generated $570K in revenue in fiscal year 2025. This represents an increase of 13.8% from the prior year.
YARROW BIOSCIENCE, INC.'s EBITDA was -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.9% from the prior year.
YARROW BIOSCIENCE, INC. reported -$26.5M in net income in fiscal year 2025. This represents an increase of 33.5% from the prior year.
YARROW BIOSCIENCE, INC. earned $-0.62 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.3% from the prior year.
Cash & Balance Sheet
YARROW BIOSCIENCE, INC. generated -$33.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2.8% from the prior year.
YARROW BIOSCIENCE, INC. held $24.0M in cash against $0 in long-term debt as of fiscal year 2025.
YARROW BIOSCIENCE, INC. had 33M shares outstanding in fiscal year 2025. This represents an increase of 124.7% from the prior year.
Margins & Returns
YARROW BIOSCIENCE, INC.'s operating margin was -5219.1% in fiscal year 2025, reflecting core business profitability. This is up 3490.9 percentage points from the prior year.
YARROW BIOSCIENCE, INC.'s net profit margin was -4646.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3304.8 percentage points from the prior year.
YARROW BIOSCIENCE, INC.'s ROE was -95.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.9 percentage points from the prior year.
Capital Allocation
YARROW BIOSCIENCE, INC. invested $19.2M in research and development in fiscal year 2025. This represents a decrease of 37.8% from the prior year.
YARROW BIOSCIENCE, INC. invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
YARW Income Statement
| Metric | Q1'26 | Q4'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $86K | N/A | $69K-65.8% | $202K+140.5% | $84K-30.6% | $121K-38.9% | $198K+102.0% | $98K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $817K | N/A | $4.9M-20.3% | $6.1M-36.8% | $9.7M-5.5% | $10.2M+40.3% | $7.3M+97.0% | $3.7M |
| SG&A Expenses | $3.1M | N/A | $2.7M-16.6% | $3.3M+3.3% | $3.2M+7.0% | $3.0M-9.9% | $3.3M-12.8% | $3.8M |
| Operating Income | -$3.8M | N/A | -$7.5M+18.0% | -$9.2M+28.0% | -$12.8M+2.5% | -$13.1M-25.9% | -$10.4M-40.9% | -$7.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | $0-100.0% | $4K | $0 | $0 | $0 |
| Net Income | -$3.6M | N/A | -$5.8M+33.2% | -$8.6M+28.4% | -$12.0M+1.1% | -$12.2M-29.2% | -$9.4M-50.5% | -$6.2M |
| EPS (Diluted) | $-0.08 | N/A | $-0.13+35.0% | $-0.20 | N/A | $-0.29-31.8% | $-0.22-46.7% | $-0.15 |
YARW Balance Sheet
| Metric | Q1'26 | Q4'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.9M-14.2% | $30.2M-32.6% | $44.7M-20.7% | $56.4M-15.7% | $66.9M-12.2% | $76.2M-12.1% | $86.6M-5.5% | $91.7M |
| Current Assets | $25.8M-14.1% | $30.0M-32.3% | $44.3M-19.2% | $54.9M-14.8% | $64.4M-12.4% | $73.5M-12.2% | $83.8M-7.1% | $90.2M |
| Cash & Equivalents | $24.6M+2.5% | $24.0M+9.0% | $22.0M-21.8% | $28.2M+41.6% | $19.9M+22.5% | $16.3M-45.0% | $29.6M+55.3% | $19.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.2M-48.4% | $2.4M-59.0% | $5.8M-52.5% | $12.3M-17.1% | $14.8M+17.0% | $12.7M+7.5% | $11.8M+41.8% | $8.3M |
| Current Liabilities | $1.2M-48.4% | $2.4M-59.0% | $5.8M-52.5% | $12.3M-17.1% | $14.8M+17.0% | $12.7M+7.7% | $11.8M+69.6% | $6.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $24.6M-11.3% | $27.8M-28.6% | $38.9M-11.9% | $44.1M-15.3% | $52.1M-18.0% | $63.5M-15.1% | $74.9M-10.2% | $83.4M |
| Retained Earnings | -$761.2M-0.5% | -$757.7M-1.6% | -$745.5M-0.8% | -$739.8M-1.2% | -$731.2M-1.7% | -$719.1M-1.7% | -$707.0M-1.3% | -$697.6M |
YARW Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.1M | N/A | -$10.8M+5.7% | -$11.5M-27.4% | -$9.0M-5.7% | -$8.5M-0.3% | -$8.5M-6.3% | -$8.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $4.7M | N/A | $4.7M-76.4% | $19.8M+55.7% | $12.7M+364.1% | -$4.8M-125.4% | $19.0M+632.9% | -$3.6M |
| Financing Cash Flow | -$15K | N/A | -$34K+60.9% | -$87K+34.1% | -$132K-6500.0% | -$2K0.0% | -$2K+60.0% | -$5K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
YARW Financial Ratios
| Metric | Q1'26 | Q4'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -4437.2% | N/A | -10930.4%-6377.5pp | -4553.0%+10649.4pp | -15202.4%-4383.4pp | -10819.0%-5568.5pp | -5250.5%+2280.1pp | -7530.6% |
| Net Margin | -4168.6% | N/A | -8340.6%-4077.7pp | -4262.9%+10049.0pp | -14311.9%-4264.8pp | -10047.1%-5296.6pp | -4750.5%+1626.0pp | -6376.5% |
| Return on Equity | -14.5% | N/A | -14.8%+4.7pp | -19.5%+3.6pp | -23.1%-4.0pp | -19.1%-6.6pp | -12.6%-5.1pp | -7.5% |
| Return on Assets | -13.9% | N/A | -12.9%+2.4pp | -15.3%+2.7pp | -18.0%-2.0pp | -16.0%-5.1pp | -10.9%-4.0pp | -6.8% |
| Current Ratio | 20.86+8.3 | 12.53+4.9 | 7.60+3.1 | 4.47+0.1 | 4.35-1.5 | 5.81-1.3 | 7.13-5.9 | 13.02 |
| Debt-to-Equity | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
What is YARROW BIOSCIENCE, INC.'s annual revenue?
YARROW BIOSCIENCE, INC. (YARW) reported $570K in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is YARROW BIOSCIENCE, INC.'s revenue growing?
YARROW BIOSCIENCE, INC. (YARW) revenue grew by 13.8% year-over-year, from $501K to $570K in fiscal year 2025.
Is YARROW BIOSCIENCE, INC. profitable?
No, YARROW BIOSCIENCE, INC. (YARW) reported a net income of -$26.5M in fiscal year 2025, with a net profit margin of -4646.1%.
What is YARROW BIOSCIENCE, INC.'s EBITDA?
YARROW BIOSCIENCE, INC. (YARW) had EBITDA of -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does YARROW BIOSCIENCE, INC. have?
As of fiscal year 2025, YARROW BIOSCIENCE, INC. (YARW) had $24.0M in cash and equivalents against $0 in long-term debt.
What is YARROW BIOSCIENCE, INC.'s operating margin?
YARROW BIOSCIENCE, INC. (YARW) had an operating margin of -5219.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is YARROW BIOSCIENCE, INC.'s net profit margin?
YARROW BIOSCIENCE, INC. (YARW) had a net profit margin of -4646.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is YARROW BIOSCIENCE, INC.'s return on equity (ROE)?
YARROW BIOSCIENCE, INC. (YARW) has a return on equity of -95.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is YARROW BIOSCIENCE, INC.'s free cash flow?
YARROW BIOSCIENCE, INC. (YARW) generated -$33.1M in free cash flow during fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is YARROW BIOSCIENCE, INC.'s operating cash flow?
YARROW BIOSCIENCE, INC. (YARW) generated -$33.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are YARROW BIOSCIENCE, INC.'s total assets?
YARROW BIOSCIENCE, INC. (YARW) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are YARROW BIOSCIENCE, INC.'s capital expenditures?
YARROW BIOSCIENCE, INC. (YARW) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does YARROW BIOSCIENCE, INC. spend on research and development?
YARROW BIOSCIENCE, INC. (YARW) invested $19.2M in research and development during fiscal year 2025.
What is YARROW BIOSCIENCE, INC.'s current ratio?
YARROW BIOSCIENCE, INC. (YARW) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.
What is YARROW BIOSCIENCE, INC.'s debt-to-equity ratio?
YARROW BIOSCIENCE, INC. (YARW) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is YARROW BIOSCIENCE, INC.'s return on assets (ROA)?
YARROW BIOSCIENCE, INC. (YARW) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is YARROW BIOSCIENCE, INC.'s cash runway?
Based on fiscal year 2025 data, YARROW BIOSCIENCE, INC. (YARW) had $24.0M in cash against an annual operating cash burn of $33.1M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is YARROW BIOSCIENCE, INC.'s Piotroski F-Score?
YARROW BIOSCIENCE, INC. (YARW) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are YARROW BIOSCIENCE, INC.'s earnings high quality?
YARROW BIOSCIENCE, INC. (YARW) has an earnings quality ratio of 1.25x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.